Bhupinder Bhullar - Articles and news items

European Drug Target Review Issue 1 2014

The publishers of European Pharmaceutical Review launch new magazine aimed at the drug discovery industry

Industry news, News / 12 May 2014 / European Pharmaceutical Review

European Drug Target Review is a business-to-business magazine featuring the latest developments in drug discovery and new drug development collaborations…

Figure 1 Advances in the development of sequencing technologies have resulted in an increase in data output with a dramatic decrease in cost. This graph compares calculated sequencing costs for one complete haploid human genome sequence (23 chromosomes, three billion bases) * estimated from literature ** marketing figures

The Sequencing Revolution: enabling personal genomics and personalised medicine

Genomics, Issue 5 2010 / 29 October 2010 / Bhupinder Bhullar, Novartis Institute for Biomedical Research

It has been 10 years since the completion of the first draft of the human genome. Today, we are in the midst of a full assault on the human genetic code, racing to uncover the genetic mechanisms that affect disease, aging, happiness, violence … and just about every imaginable human variation. Advances in DNA sequencing technology have enabled individuals to have their own genomes sequenced rapidly, cheaply and in astonishing detail. The sequencing revolution is also changing the way the pharmaceutical industry develops, tests and targets new medicines.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...